These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 18788407)

  • 21. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
    Vaziri ND
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Background of measures against chronic kidney disease].
    Hishida A
    Nihon Rinsho; 2008 Sep; 66(9):1639-44. PubMed ID: 18788388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Lipid management--treatment goal and strategy].
    Koshiyama H
    Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early intervention strategies to lower cardiovascular risk in early nephropathy: focus on dyslipidemia.
    Sorrentino MJ
    Cardiol Clin; 2010 Aug; 28(3):529-39. PubMed ID: 20621255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Statins: what is their place in the treatment of chronic kidney insufficiency?].
    Ponte B; Bourquin V; Stoermann-Chopard C
    Rev Med Suisse; 2009 Feb; 5(192):463-4, 466-8. PubMed ID: 19317313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statins in patients with chronic kidney disease: why, who and when?
    Gluba A; Rysz J; Banach M
    Expert Opin Pharmacother; 2010 Nov; 11(16):2665-74. PubMed ID: 20977401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials.
    Chan DT; Irish AB; Dogra GK; Watts GF
    Atherosclerosis; 2008 Feb; 196(2):823-34. PubMed ID: 17343861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Gastroenterological aspects of atherosclerosis].
    Zvenigorodskaia LA; Samsonova NG; Efremov LI; Cherkashova EA; Lazebnik LB
    Eksp Klin Gastroenterol; 2011; (2):31-6. PubMed ID: 21560640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New concept of chronic kidney disease and blockade of renin-angiotensin system].
    Takeda T; Gejyo F
    Nihon Rinsho; 2007 Sep; 65(9):1727-33. PubMed ID: 17877002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing outcomes in patients with cardiovascular disease and chronic kidney disease.
    Marrs JC
    Am J Manag Care; 2011 Dec; 17 Suppl 15():S403-11. PubMed ID: 22214475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Epidemiology of CKD in Japan].
    Iseki K
    Nihon Rinsho; 2008 Sep; 66(9):1650-6. PubMed ID: 18788390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.
    Khurana M; Silverstein DM
    Pediatr Nephrol; 2015 Dec; 30(12):2073-84. PubMed ID: 25801207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Integrated care and expected outcomes over the progression of CKD (chronic kidney disease)].
    Kimura G
    Nihon Rinsho; 2008 Sep; 66(9):1807-13. PubMed ID: 18788414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of lipid disorders in obesity.
    Tonstad S; Després JP
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):1069-80. PubMed ID: 21878051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of lipid abnormalities associated with end-stage renal disease.
    Liu J; Kalantarinia K; Rosner MH
    Semin Dial; 2006; 19(5):391-401. PubMed ID: 16970739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease.
    Rodriguez-Iturbe B; Correa-Rotter R
    Expert Opin Pharmacother; 2010 Nov; 11(16):2687-98. PubMed ID: 20426701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.